Piper Sandler Upgrades Tempus AI to Overweight Rating

Piper Sandler upgraded the stock rating of Tempus AI Inc from Neutral to Overweight on September 1, 2026, while increasing the price target from $56 to $76. The investment firm cited three primary growth drivers: the pending acquisition of Personalis, a positive INTerpath-001 readout, and the Food and Drug Administration approval of tumor-only xT CDx, which enables the company to pursue unified ADLT pricing.

Tempus AI recently reported second-quarter 2026 financial results featuring a 22% year-over-year revenue increase to $382.5 million. The company also reported an adjusted loss of $0.04 per share, which was narrower than analysts had expected.

Market sentiment remains mixed among other financial institutions. While Canaccord Genuity, BTIG, and H.C. Wainwright maintain Buy ratings, Stifel lowered its price target for the company to $50, citing concerns over margins.